Facebook
Twitter
LinkedIn
Forward2024 Seattle Cellular Therapy Summit - Enduring Recorded Webcast
This accredited continuing education activity “2024 Seattle Cellular Therapy Summit: Updates & Focus on Accessibility ”, is recorded from the live conference held from 8/16/2024 to 8/17/2024.
If you participated in the live conference titled - 2024 Seattle Cellular Therapy Summit: Updates & Focus on Accessibility from 8/16/2024 to 8/17/2024 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that conference from 8/16/2024 to 8/17/2024. However, you may enroll in this activity to review the contents as needed.
This recorded webcast, 2024 Seattle Cellular Therapy Summit: Updates & Focus on Accessibility (SCTS24), is one of the largest gatherings of cancer care professionals interested in current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. SCTS24 featured lectures, case-based presentations, panel discussions, and debates among leaders across the spectrum of cellular therapy treatment. This conference brought together oncology professionals, cancer disparity researchers, and other stakeholders to discuss optimal clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. A focus of the conference was to explore different therapeutic agents in a clinical context and also to discuss how to utilize these therapeutic options to effectively contribute to patient care. A distinctive feature of this conference was case-based discussions that described a problem, how it was solved, and the lessons learned.
SCTS24 is an accredited continuing education activity (CME activity) that fostered collaborative interdisciplinary interactions and partnerships to stimulate the development of new advances in patient-centered care. Leading experts discussed how to reduce barriers to using cellular therapy as well as evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.
REGISTRATION FEES:
This activity is free for all.
Target Audience
- Hematologists/Medical Oncologists
- Oncology fellows
- Oncology nurses
- NPs/PAs
- Oncology pharmacists
Organizing Committee
Program Director:
Dr. Binay Shah - Binaytara Foundation
Conference Co-Chairs:
Dr. Mazyar Shadman - University of Washington, Fred Hutchinson Cancer Center
Dr. Krish Patel - Swedish Cancer Institute
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review indications and outcomes of approved cellular therapies in hematologic malignancies
- Identify emerging cellular therapies in hematologic malignancies and solid tumors
- Identify and manage complications after cellular therapy
- State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies
This educational activity features recorded videos from the live conference titled 2024 Seattle Cellular Therapy Summit: Updates & Focus on Accessibility
held August 16-17, 2024.
The videos are placed in the following order. Feel free to view the content that is relevant to you.
Participants should claim continuing education credits to the extent of their participation.
1 hour and 15 minutes — Session 1: Updates on Approved CAR-T Therapies
Session Chair: Mazyar Shadman, MD
Updates in CAR-T Therapy for Lymphoma - Mazyar Shadman, MD
Updates in CAR-T Therapy for Myeloma - Swathi Namburi, MD
Updates in CAR-T Therapy for Leukemia - Joseph Tuscano, MD
Panel Discussion
1 hour and 30 minutes — Session 2: Immunotherapy for Solid Tumors
Session Chair: Kelly Paulson, MD
Immunotherapy for Solid Tumors - Future Direction - Lawrence Fong, MD
TIL Therapy for Melanoma - Kelly Paulson, MD
TCR Therapy for Sarcoma - Elizabeth Loggers, MD, PhD
Cellular Immunotherapy for Gynecologic Malignancies - Fernanda Musa, MD
Cellular Immunotherapy for Breast Cancer - Jennifer Specht, MD
Panel Discussion
1 hour — Session 3: Complications
Session Chairs: Mazyar Shadman, MD & Krish Patel, MD
Advances in Prevention and Management of CRS and ICANS - Jordan Gauthier, MD, MSc
Prevention and Treatment of Infectious Complications after CAR-T Therapy - Joshua Hill, MD
Second Malignancies after CAR-T Therapy - Alexandre Hirayama, MD
CAR-T Therapy for Autoimmune Diseases - Krish Patel, MD
Panel Discussion
45 minutes — Session 4: Access to Cellular Immunotherapy
Session Chair: Krish Patel, MD
Cellular Immunotherapy in the Outpatient Setting - Aravind Ramakrishnan, MD
Improving Access to CAR-T Therapy - Marc Hoffman, MD
Panel Discussion - Lisa Getzendaner, PA-C, MHS; Julia Parker, ARNP
2 hours and 5 minutes — Session 5: Debates in Myeloma
Session Chairs: Rahul Banerjee, MD; Swathi Namburi, MD; Thomas Martin, MD
What is the Right Sequence of Immunotherapy in Multiple Myeloma?
Case Presentation - Vivian Liu, MD
Bispecific Antibodies before CAR-T Therapy - Meera Mohan, MD, MS, FACP
CAR-T Therapy before Bispecific Antibodies - Saad Usmani, MD, MBA, FACP, FASCO
What is the Best Second Line Treatment Option for Myeloma?
Favor CAR-T Therapy for Second Line - Gurbakhash Kaur, MD
Favor Non CAR-T Options for Second Line - Rahul Banerjee, MD
Is Immunotherapy an Option for Smoldering Myeloma?
Case Presentation - Nico Ruiz Lopez, MD
Favor Immunotherapy for Smoldering Myeloma - Yuxin Liu, MD
Favor Conventional (Non-Immunotherapy) for Smoldering Myeloma - Louis Williams, MD, MBA
Favor No Intervention for Smoldering Myeloma - Samuel Rubinstein, MD
Novel Target CAR-T - Swathi Namburi, MD
Panel Discussion
1 hour and 25 minutes — Session 6: Debates in Lymphoma Part 1
Session Chair: Krish Patel, MD
Should Anti-CD19 Therapies Be Used Before CD19 Targeted Car-T therapy?
Case Presentation - Hannah Abrams, MD
YES - Mehdi Hamadani, MD
NO - Matthew Lunning, DO
What is the Best Treatment Option for Post CD19 CAR-T?
Case Presentation - Paolo Lopedote, MD
Bispecific Antibodies - Tycel Phillips, MD
Other Cellular Therapy Options - Matthew Frank, MD, PhD
Immunotherapy for First Line DLBCL
CAR-T as the Best Immunotherapy Option for First Line - Sattva Neelapu, MD
Bispecific Antibodies as Best First-Line Option for First Line - Ryan Lynch, MD
Panel Discussion
2 hours — Session 7: Debates in Lymphoma Part 2
Session Chair: Alexey Danilov, MD, PhD
Treatment Strategy for CLL Patients With “Double Refractory” Disease
Case Presentation - Laura Samples, MD
CAR-T (Liso-Cel) - Nirav Shah, MD
Pirtobrutinib - Catherine Coombs, MD
Allogeneic Stem Cell Transplant - Mazyar Shadman, MD
With Liso-Cel Approval, Which CAR-T Product is Preferred for MCL?
Brexu-Cel - Michael Jain, MD, PhD
Liso-Cel - Alexey Danilov, MD, PhD
Which Immunotherapy Option is More Promising for T-cell Lymphoma?
Antibody-Based Immunotherapy - Christina Poh, MD
CAR-T - Rayne Rouce, MD
Panel Discussion
1 hour and 25 minutes — Session 8: Debates in Leukemia
Session Chair: Filippo Milano, MD, PhD
Current State of Cellular Immunotherapy for AML - Monica L. Guzman, PhD
CAR-T Therapy of Choice for ALL
Brexu-Cel - Ryan Cassaday, MD
Obe-Cel - Nitin Jain, MD
Bispecific Antibodies or CAR-T for Relapsed FL
Case Presentation - Blossom Raychaudhuri, MD
Favor CAR-T - Paolo Strati, MD
Favor Bispecific Antibodies - Elizabeth Budde, MD, PhD
The Most Promising Immunotherapy Option for Richter Transformation
Case Presentation: Blossom Raychaudhuri, MD
CAR-T - Adam Kittai, MD
Bispecific Antibodies - Herbert Eradat, MD
Panel Discussion
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Course Director(s)
Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.
Conference Chair(s)
Krish Patel, MD has a financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Lilly; financial relationship (Professional Services) with Sana; financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Janssen/Pharmacyclics; financial relationship (Professional Services) with Xencor; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with Merck.
Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with BeiGene; financial relationship (Employment) with BMS; financial relationship (Professional Services) with Kite Pharma ; financial relationship (Professional Services) with Nurix; financial relationship (Professional Services) with Mustang Bio ; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with MorphoSys/Incyte; financial relationship (Professional Services) with Janssen ; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Genmab; financial relationship (Stock Options) with Koi Biotherapeutics; financial relationship (Professional Services) with Fate therapeutics; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Vincerx ; financial relationship (Professional Services) with Eli Lily ; financial relationship (Professional Services) with BMS.
Session Chair(s)
Rahul Banerjee, MD, FACP has a financial relationship (Grant Or Contract) with i3 Health; financial relationship (Independent contractor) with Clearview Healthcare Partners; financial relationship (Independent contractor) with BMS; financial relationship (Grant Or Contract) with Clinical Care Options; financial relationship (Independent contractor) with Guidepoint Global; financial relationship (Grant Or Contract) with Pack Health; financial relationship (Grant Or Contract) with Curio Science; financial relationship (Independent contractor) with Sanofi Pasteur; financial relationship (Independent contractor) with Janssen Oncology; financial relationship (Independent contractor) with SparkCures; financial relationship (Independent contractor) with Genentech/Roche.
Alexey Danilov, MD, PhD has a financial relationship (Independent contractor) with Lilly; financial relationship (Grant Or Contract) with Nurix; financial relationship (Independent contractor) with Beigene; financial relationship (Grant Or Contract) with Bayer; financial relationship (Independent contractor) with Abbvie; financial relationship (Grant Or Contract) with MEI; financial relationship (Independent contractor) with Astra Zeneca.
Filippo Milano has no relevant financial relationships to disclose at this time.
Swathi Namburi, MD has no relevant financial relationships to disclose at this time.
Kelly Paulson, MD, PhD has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)
Lihua Budde, M.D., Ph.D. has a financial relationship (Financial Support) with AstraZeneca; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Financial Support) with Roche; financial relationship (Grant Or Contract) with Merck; financial relationship (Financial Support) with Genentech; financial relationship (Financial Support) with Janssen; financial relationship (Financial Support) with ADC Therapeutics; financial relationship (Grant Or Contract) with Amgen.
Ryan Cassaday, MD has a financial relationship (Grant Or Contract) with Servier; financial relationship (Independent contractor) with Jazz; financial relationship (Stock Options) with Seagen; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Independent contractor) with Amgen; financial relationship (Other) with Autolus; financial relationship (Grant Or Contract) with Kite; financial relationship (Grant Or Contract) with Vanda; financial relationship (Independent contractor) with Pfizer; financial relationship (Grant Or Contract) with Amgen; financial relationship (Grant Or Contract) with Incyte; financial relationship (Independent contractor) with Kite.
Catherine Coombs has a financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with MEI Pharma; financial relationship (Independent contractor) with AbbVie; financial relationship (Independent contractor) with Lilly; financial relationship (Independent contractor) with TG therapeutics; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Mingsight; financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Allogene; financial relationship (Independent contractor) with Octapharma.
Saurabh Dahiya has no relevant financial relationships to disclose at this time.
Alexey Danilov, MD, PhD has a financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Lilly; financial relationship (Grant Or Contract) with Nurix; financial relationship (Independent contractor) with Beigene; financial relationship (Grant Or Contract) with Bayer; financial relationship (Independent contractor) with Abbvie; financial relationship (Grant Or Contract) with MEI.
Herbert Eradat has a financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with ADC Therapeutics; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Incyte; financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Genmab.
Lawrence Fong, MD has a financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Dendreon; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Roche/Genentech.
Matthew Frank, MD PhD has a financial relationship (Grant Or Contract) with Cargo Therapeutics; financial relationship (Travel) with Kite Pharma-Gilead; financial relationship (Grant Or Contract) with Adaptive Biotechnology; financial relationship (Grant Or Contract) with Kite Pharma-Gilead; financial relationship (Grant Or Contract) with Allogene Therapeutics; financial relationship (Travel) with Cargo Therapeutics.
Jordan Gauthier, MD, MSc has a financial relationship (Other) with Sobi; financial relationship (Other) with MorphoSys; financial relationship (Grant Or Contract) with Angiocrine Bioscience; financial relationship (Other) with Kite Pharma; financial relationship (Grant Or Contract) with Celgene (a BMS company); financial relationship (Other) with Janssen; financial relationship (Grant Or Contract) with Juno Therapeutics (a BMS company); financial relationship (Other) with Century Therapeutics; financial relationship (Other) with Legend Biotech; financial relationship (Grant Or Contract) with Sobi; financial relationship (Grant Or Contract) with Faron Pharmaceuticals.
Monica Guzman has no relevant financial relationships to disclose at this time.
Mehdi Hamadani has a financial relationship (Other) with ADC Therapeutics, AstraZeneca, Bei Gene, Kite. ;financial relationship (Professional Services) with ADC Therapeutics, Omeros, CRISPR, BMS, Kite, AbbVie, Caribou, Genmab.
Joshua Hill, MD has a financial relationship (Financial Support) with GeoVax; financial relationship (Independent contractor) with CSL Behring; financial relationship (Independent contractor) with Gilead; financial relationship (Independent contractor) with Modulus; financial relationship (Independent contractor) with Up-to-Date; financial relationship (Financial Support) with Deverra; financial relationship (Independent contractor) with Century Therapeutics; financial relationship (Independent contractor) with Gilead; financial relationship (Independent contractor) with Moderna; financial relationship (Independent contractor) with Takeda; financial relationship (Financial Support) with Allovir; financial relationship (Financial Support) with Oxford Immunotec; financial relationship (Independent contractor) with Allovir; financial relationship (Independent contractor) with GeoVax; financial relationship (Independent contractor) with Karius; financial relationship (Independent contractor) with SentiBio; financial relationship (Independent contractor) with Gilead Australia; financial relationship (Financial Support) with Merck; financial relationship (Independent contractor) with Eversana; financial relationship (Independent contractor) with Grifols; financial relationship (Independent contractor) with Pfizer (previously Medpace/Amplyx.
Alexandre Hirayama, MD has a financial relationship (Grant Or Contract) with Nektar Therapeutics; financial relationship (Grant Or Contract) with Juno Therapeutics, a Bristol Myers Squibb Company.
Marc Hoffmann, Associate Professor; Director, Lymphoma Program has a financial relationship (Independent contractor) with Astra-Zeneca; financial relationship (Independent contractor) with AbbVie; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with BeiGene; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Novartis; financial relationship (Independent contractor) with ADC Therapeutics.
Michael Jain has a financial relationship (Professional Services) with Myeloid Therapeutics; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with Kite/Gilead.
Nitin Jain, MD has a financial relationship (Gift) with Pharmacyclics; financial relationship (Gift) with AstraZeneca; financial relationship (Gift) with Cellectis; financial relationship (Gift) with Genentech; financial relationship (Gift) with Beigene; financial relationship (Gift) with AbbVie; financial relationship (Gift) with Precision Bio; financial relationship (Gift) with Janssen; financial relationship (Gift) with Kite; financial relationship (Gift) with Fate Therapeutics.
Gurbakhash Kaur, MD has a financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with Arcellx; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Kedrion; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Pfizer.
Adam Kittai, MD has a financial relationship (Independent contractor) with BeiGene; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Grant Or Contract) with BeiGene; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Independent contractor) with BMS.
Yuxin Liu, MD has no relevant financial relationships to disclose at this time.
Elizabeth Loggers, MD, PhD has no relevant financial relationships to disclose at this time.
Matthew Lunning, Matt Lunning, D.O., F.A.C.P. has a financial relationship (Professional Services) with Astellas; financial relationship (Grant Or Contract) with Curis; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Morphosys; financial relationship (Professional Services) with Regeneron; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Astra Zeneca; financial relationship (Professional Services) with CRISPR; financial relationship (Professional Services) with Fate Therapetuics; financial relationship (Professional Services) with Ipsen; financial relationship (Professional Services) with Miltenyi; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with Takeda; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with EUSA; financial relationship (Professional Services) with InstilBio; financial relationship (Professional Services) with Loxo; financial relationship (Professional Services) with Nurix; financial relationship (Professional Services) with SeaGen; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Daiichi Sankyo; financial relationship (Professional Services) with GenMab; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Acrotech.
Ryan Lynch has a financial relationship (Grant Or Contract) with RAPT; financial relationship (Grant Or Contract) with SeaGen; financial relationship (Other) with Janssen; financial relationship (Grant Or Contract) with TG Therapeutics; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Cyteir; financial relationship (Other) with Merck; financial relationship (Grant Or Contract) with Incyte; financial relationship (Other) with Seagen; financial relationship (Grant Or Contract) with Janssen.
Thomas Martin, MD has a financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with GSK; financial relationship (Grant Or Contract) with Janssen; financial relationship (Grant Or Contract) with Sanofi.
Meera Mohan, MD, MS has a financial relationship (Professional Services) with MJH; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Blood Cancer Today; financial relationship (Professional Services) with Sanofi.
Fernanda Musa, MD MS has a financial relationship (Professional Services) with GSK ; financial relationship (Professional Services) with Duality Bio/ BioNTech; financial relationship (Professional Services) with OncLive; financial relationship (Professional Services) with GSK; financial relationship (Professional Services) with Topline Bio; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Daiichi Sankyo; financial relationship (Professional Services) with Astra Zeneca; financial relationship (Professional Services) with AADI.
Swathi Namburi, MD has no relevant financial relationships to disclose at this time.
Sattva Neelapu, MD has a financial relationship (Professional Services) with Kite/Gilead, Merck, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, Morphosys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda, Synthekine, Carsgen, Appia B; financial relationship (Grant Or Contract) with Kite/Gilead, BMS, Allogene, Precision Biosciences, Adicet Bio, Sana Biotechnology, and Cargo Therapeutics.
Krina Patel, MD has a financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Legend Biotech; financial relationship (Independent contractor) with BMS.
Krish Patel, MD has a financial relationship (Professional Services) with Sana; financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Lilly; financial relationship (Professional Services) with Xencor; financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Janssen/Pharmacyclics; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Pfizer.
Kelly Paulson, MD, PhD has no relevant financial relationships to disclose at this time.
Tycel Phillips, MD has a financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Kite; financial relationship (Grant Or Contract) with Abbvie; financial relationship (Independent contractor) with Bayer; financial relationship (Independent contractor) with Epizyme; financial relationship (Independent contractor) with Incite; financial relationship (Grant Or Contract) with Genentech; financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Eli Lily; financial relationship (Independent contractor) with Gilead; financial relationship (Independent contractor) with ADCT; financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Genmab; financial relationship (Independent contractor) with Fencer.
Christina Poh, MD has a financial relationship (Other) with Astex; financial relationship (Other) with Ipsen; financial relationship (Other) with Seagen; financial relationship (Other) with Dren Bio; financial relationship (Other) with Acrotech.
Aravind Ramakrishnan, MD has a financial relationship (Travel) with AstraZeneca.
Rayne Rouce has a financial relationship (Other) with Pfizer; financial relationship (Other) with Novartis.
Samuel Rubinstein, Clinical Assistant Professor of Medicine has a financial relationship (Independent contractor) with LAVA Therapeutics; financial relationship (Independent contractor) with Sanofi; financial relationship (Independent contractor) with Janssen.
Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with MorphoSys/Incyte; financial relationship (Professional Services) with Janssen ; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Genmab; financial relationship (Stock Options) with Koi Biotherapeutics; financial relationship (Professional Services) with Fate therapeutics; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Vincerx ; financial relationship (Professional Services) with Eli Lily ; financial relationship (Professional Services) with Nurix; financial relationship (Professional Services) with Mustang Bio ; financial relationship (Professional Services) with BeiGene; financial relationship (Employment) with BMS; financial relationship (Professional Services) with Kite Pharma .
Nirav Shah, MD has a financial relationship (Independent contractor) with BMS-Juno; financial relationship (Independent contractor) with Epizyme; financial relationship (Independent contractor) with Miltenyi Biotec; financial relationship (Stock) with Tundra Therapeutics; financial relationship (Independent contractor) with Loxo-Lilly; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with TG Therapeutics; financial relationship (Independent contractor) with Incyte; financial relationship (Independent contractor) with Seattle Genetics; financial relationship (Independent contractor) with Kite.
Jennifer Specht, MD has a financial relationship (Professional Services) with Sensei Biotherapeutics; financial relationship (Grant Or Contract) with Xencor; financial relationship (Professional Services) with Lyell Immunopharma Inc; financial relationship (Professional Services) with GE Healthcare; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Abbvie ; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Other) with A2 Biotherapeutics ; financial relationship (Grant Or Contract) with Seattle Genetics; financial relationship (Grant Or Contract) with Celcuity; financial relationship (Grant Or Contract) with Carisma Therapeutics; financial relationship (Professional Services) with Volastra Therapeutics; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Lyell Immunopharma.
Paolo Strati, MD has a financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with Kite-Gilead; financial relationship (Professional Services) with Astrazeneca; financial relationship (Professional Services) with Roche Genentech.
Joseph Tuscano, md has a financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Seagen; financial relationship (Grant Or Contract) with Regeneron; financial relationship (Grant Or Contract) with ADC; financial relationship (Grant Or Contract) with ABBVIE.
Saad Usmani, Chief of Myeloma Service has a financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with GSK; financial relationship (Professional Services) with Regeneron; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with BMS.
Louis Williams has a financial relationship (Other) with Abbvie Inc.; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Bristol Meyer Squibb.
Case Presenter(s)
Hannah Abrams, MD has no relevant financial relationships to disclose at this time.
Lisa Getzendaner, PA-C, MHS has a financial relationship (Independent contractor) with Kite Pharmaceuticals.
Vivian Liu has no relevant financial relationships to disclose at this time.
Paolo Lopedote, MD has no relevant financial relationships to disclose at this time.
Julia Parker has no relevant financial relationships to disclose at this time.
Blossom Suravi Raychaudhuri, MD has a financial relationship (Stock) with Moderna; financial relationship (Stock) with Pfizer; financial relationship (Stock) with Biontech.
Jorge Ruiz Lopez, MD has no relevant financial relationships to disclose at this time.
Laura Samples, MD has no relevant financial relationships to disclose at this time.
Important Information about Claiming CME for this activity:
If you participated in the live course titled -2024 Seattle Cellular Therapy Summit: Updates & Focus on Accessibility on 08/16/24-08/17/24 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This was recorded from the live course on 08/16/24-08/17/24.
Available Credit
- 11.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 0.00 Attendance
- 11.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.25 Contact Hours.